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Abstract
Animal studies have shown that the calcineurin inhibitors (CNIs) cyclosporine and tacroli-
mus can activate the thiazide-sensitive NaCl cotransporter (NCC). A common side effect of
CNIs is hypertension. Renal salt transporters such as NCC are excreted in urinary extracel-
lular vesicles (uEVs) after internalization into multivesicular bodies. Human studies indicate
that CNIs also increase NCC abundance in uEVs, but results are conflicting and no relation-
ship with NCC function has been shown. Therefore, we investigated the effects of CsA and
Tac on the abundance of both total NCC (tNCC) and phosphorylated NCC at Thr60 phos-
phorylation site (pNCC) in uEVs, and assessed whether NCC abundance in uEVs predicts
the blood pressure response to thiazide diuretics. Our results show that in kidney transplant
recipients treated with cyclosporine (n = 9) or tacrolimus (n = 23), the abundance of both
tNCC and pNCC in uEVs is 4–5 fold higher than in CNI-free kidney transplant recipients
(n = 13) or healthy volunteers (n = 6). In hypertensive kidney transplant recipients, higher
abundances of tNCC and pNCC prior to treatment with thiazides predicted the blood pres-
sure response to thiazides. During thiazide treatment, the abundance of pNCC in uEVs
increased in responders (n = 10), but markedly decreased in non-responders (n = 8). Thus,
our results show that CNIs increase the abundance of both tNCC and pNCC in uEVs, and
these increases correlate with the blood pressure response to thiazides. This implies that
assessment of NCC in uEVs could represent an alternate method to guide anti-hypertensive
therapy in kidney transplant recipients.
PLOS ONE | https://doi.org/10.1371/journal.pone.0176220 April 21, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Tutakhel OAZ, Moes AD, Valdez-Flores
MA, Kortenoeven MLA, Vrie MvD, Jeleń S, et al.
(2017) NaCl cotransporter abundance in urinary
vesicles is increased by calcineurin inhibitors and
predicts thiazide sensitivity. PLoS ONE 12(4):
e0176220. https://doi.org/10.1371/journal.
pone.0176220
Editor: Jaap A. Joles, University Medical Center
Utrecht, NETHERLANDS
Received: November 29, 2016
Accepted: April 8, 2017
Published: April 21, 2017
Copyright: © 2017 Tutakhel et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All the dataset
underlying the findings in the manuscript are
uploaded as Supporting Information files. Data that
are from the Group 1, Radboud study whose
authors may be contacted at rene.
bindels@radboudumc.nl Data that are from the
Group 2, Erasmus MC study whose authors may
be contacted at e.j.hoorn@erasmusmc.nl Data that
are from the Animal study whose authors may be
contacted at rene.bindels@radboudumc.nl.
Introduction
The calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus (Tac) are widely used
to prevent rejection of transplanted organs. CNIs inhibit the calcineurin-mediated immune
response in T-cells [1]. Although both CsA and Tac exert their principal immunosuppressive
effects through inhibition of the same target protein, calcineurin, they differ in cytoplasmic-
binding proteins, namely cyclophilins and FKBP12 for CsA and Tac, respectively. CsA and
Tac also vary with respect to their immunosuppressive potency [2,3] and side effects [4–6]. A
common side effect of CNIs is hypertension, although CsA appears more hypertensinogenic
than Tac [6–8]. CNI-induced hypertension may be accompanied by hyperkalemia and meta-
bolic acidosis [9,10]. The clinical characteristics of CNI-treated patients sometimes resemble
that of familial hyperkalemic hypertension (FHHt) [11,12], also known as Gordon syndrome
[13] or pseudohypoaldosteronism type II [14] (OMIM 145260). FHHt results from mutations
in WNK [with no lysine (K)] kinases WNK1 and WNK4 [15], Kelch-like 3 (KLHL3) [16], or
Cullin 3 (CUL3) [17], which all lead to a gain-of-function in the thiazide-sensitive NaCl
cotransporter (NCC) resulting in salt retention in the distal part of the nephron [15,18–20].
Several studies have shown that CNIs increase NCC activity possibly contributing to hyperten-
sion [21,22]. Melnikov et al. demonstrated that rats treated with CsA develop a phenotype sim-
ilar to that of FHHt, which they attributed to an increase in WNK4 abundance in the kidney
[23]. This phenomenon is supported by in vitro studies showing that the abundance of WNK4
and ultimately of total NCC (tNCC) and phosphorylated, or active, NCC (pNCC), is increased
in immortalized mouse distal convoluted tubule (mDCT) cells treated with CsA [23]. Hoorn
et al. revealed that Tac-induced hypertension in mice is predominantly mediated by an
increase in pNCC abundance, possibly through an effect of the NCC-regulating kinases
WNK3, WNK4, and STE20/SPS1-related proline/alanine-rich kinase (SPAK) [21]. Recent evi-
dence suggests that in mice, Tac prevents the high potassium stimulated NCC dephosphoryla-
tion [24]. Additionally, it has been demonstrated that Tac acts directly on kidney tubule cells
expressing NCC to cause hypertension, and that inhibition of calcineurin is required for this
effect [22].
In humans, urinary extracellular vesicles (uEVs), including exosomes, have been extensively
characterized and studied as non-invasive biomarkers for renal tubular disorders [25–28].
uEVs are nanosized membranous vesicles released from all cells lining the nephron. Alter-
ations in the expression of different proteins present in the epithelial cells of the distal convo-
luted tubule (DCT), including NCC, are reflected in the composition of uEVs [29–32].
Patients with FHHt have an increased NCC abundance in uEVs [31–33], while patients with
Gitelman syndrome exhibit a decreased NCC abundance in uEVs [28,34]. In humans, miner-
alocorticoid administration rapidly increased the abundance of tNCC and pNCC in uEVs
[35], possibly mediated by a reduced plasma potassium concentration secondary to epithelial
sodium channel (ENaC) activation [35,36]. This suggests that NCC abundance in uEVs reflects
the actual state of NCC expression in the epithelial cells of the DCT. Accordingly, we previ-
ously showed that in patients with primary aldosteronism, pNCC increased similarly in kidney
and uEVs [31].
Although protein abundance and characterization in uEVs can potentially be used as bio-
markers for some diseases [28,31–34], only a few studies have been conducted to investigate
the role of NCC in CNI-induced hypertension in humans. Esteva-Font et al. found a positive
correlation between plasma CsA levels and NCC abundance in uEVs of CsA-treated kidney
transplant recipients [37]. Rojas-Vega et al. showed an increased abundance of NCC in uEVs
of Tac-treated hypertensive kidney transplant recipients [38]. Although these studies showed
the stimulatory effect of CNIs on NCC abundance in uEVs of kidney transplant recipients,
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they did not explore the relationship between NCC abundance and blood pressure in kidney
transplant recipients. Therefore, in the present study, we performed a large-scale study to
investigate the effect of CsA and Tac on the abundance of both tNCC and pNCC in uEVs, and
assessed whether NCC abundance in uEVs predicts the blood pressure response to thiazide
diuretics. Finally, in order to confirm the effect of CNIs on NCC in the kidney, an ex vivo
study was conducted in mice cortical tubules exposed to CsA.
Materials and methods
Study design and population
Two groups of kidney transplant recipients using CNIs were studied. Group 1 was recruited at
the Radboud university medical center, in Nijmegen, The Netherlands, and consisted of a ran-
domly selected cohort of 45 kidney transplant recipients and 6 healthy volunteers of whom
uEVs were isolated and analyzed. The kidney transplant recipients used CsA (n = 9), Tac
(n = 23) or a CNI-free immunosuppressive regimen (n = 13) for at least 6 months and were
matched for age and gender. Kidney transplant recipients who had been using thiazide diuret-
ics or aldosterone antagonists after transplantation were excluded. Group 2 consisted of Tac-
treated hypertensive kidney transplant recipients (median of 2.4 years after kidney transplanta-
tion), recruited from a clinical trial studying the anti-hypertensive effect of thiazide-type
diuretic chlorthalidone at the Erasmus Medical Center, in Rotterdam, The Netherlands [39].
Patients with an office blood pressure>140/90 mmHg were invited for ambulatory blood
pressure measurement. In this group, 18 patients with an average daytime systolic blood pres-
sure >140 mmHg were enrolled and followed for 8 weeks chlorthalidone (12–25 mg once
daily) treatment. Patients who responded to chlorthalidone (‘responders’, decrease of10
mmHg in average daytime systolic blood pressure, n = 10) were compared with patients who
did not respond to chlorthalidone (‘non-responders’, no change or an increase in average day-
time systolic blood pressure, n = 8). All participants gave written informed consent and both
cohorts were approved by Medical Ethics Committee (CMO09/073 for Radboud university
medical center and MEC-2012-417 for Erasmus Medical Center) and this study was conducted
according to the principles expressed in the Declaration of Helsinki.
Urine collection and isolation of extracellular vesicles
In Group 1, second-morning mid-stream urine sample was collected. In Group 2, second-
morning mid-stream urine was collected just before starting and after 8 weeks of chlorthali-
done treatment. In both groups, immediately after urine collection, the protease inhibitors
(50 μmol/L phenylmethylsulfonyl fluoride, 20 μmol/L aprotinin, 10 μmol/L pepstatin A, and
20 μmol/L leupeptin) were added to the urine to reduce protein degradation. All samples were
directly stored at -80˚C. uEVs were isolated as reported previously [29–31,40]. In brief, 10 to
40 mL of the collected urine samples were centrifuged at 17,000 × g for 15 minutes at 24˚C in
an ultracentrifuge (Sorvall™ WX Floor Ultra Centrifuges, Thermo Scientific, Asheville, NC,
USA) with a 70.1Ti rotor. The supernatant was stored at room temperature for 25 minutes.
The pellet was resuspended in 50 μL of 3.24 mol/L dithiothreitol and 200 μL isolation solution
(10 mmol/L triethanolamine, 250 mmol/L sucrose, HCl pH 7.6) and centrifuged at 17,000 × g
for 15 minutes at 24˚C. Next, the supernatant was collected and combined with the superna-
tant obtained from the previous centrifugation, and the combined supernatants were centri-
fuged at 170,000 × g for 2.5 hours at 24˚C. Pellets containing uEVs were solubilized in
Laemmli sample buffer (0.6% w/v SDS, 3% v/v glycerol, 18 mmol/L Tris-HCl pH 6.8 and
0.003% w/v bromophenol blue). All the samples were preheated for 15 minutes at 65˚C before
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immunoblotting. Urinary creatinine was measured according to Jaffe’s method with the use of
a colorimetric assay (Labor und Technik, Berlin, Germany).
Mouse cortical tubule suspension
Animal protocols were approved by the board of the Institute of Biomedicine, University of
Aarhus. The animal protocols comply with the European Community guidelines for the use of
experimental animals, were approved and performed under a license issued for the use of
experimental animals by the Danish Ministry of Justice (Dyreforsøgstilsynet). For this study
mice were anesthetized using isoflurane inhalation, followed by cervical dislocation. Both kid-
neys from a male wildtype C57BL/6J mouse were removed and dissected into approximately 1
mm pieces and placed into 4 mL of enzyme solution containing 1.5 mg/mL collagenase type B
(Worthington Labs, Lakewood, NJ, USA) in basic buffer (125 mmol/L NaCl, 30 mmol/L glu-
cose, 0.4 mmol/L KH2PO4, 1.6 mmol/L K2HPO4, 1 mmol/L MgSO4, 10 mmol/L Na-acetate, 1
mmol/L α-ketoglutarate, 1.3 mmol/L Ca-gluconate, 5 mmol/L glycine, 48 μg/mL trypsin
inhibitor, and 50 μg/mL DNase, Tris-HCl pH 7.4). Samples were mixed continuously at 37˚C
using a benchtop orbital mixer. Samples were incubated for 15 minutes at 22˚C to let the
large fragments sink down to the bottom of the tube. Next, 2 mL of the enzyme solution was
removed and replaced with 2 mL of basic buffer. After 10 minutes’ incubation at 4˚C, an addi-
tional 2 mL of basic buffer was added, and samples were incubated for an additional 10 min-
utes at 22˚C. Large fragments were allowed to settle, the supernatant was removed and
centrifuged at 200 × g for 2 minutes. The pellet was resuspended in 5 mL of basic buffer (buffer
B) (120 mmol/L NaCl, 30 mmol/L glucose, 1 mmol/L CaCl2, 1 mmol/L MgCl2, 1 mmol/L
Na2HPO4, 1 mmol/L Na2SO4, 15 mmol/L Na-HEPES, Tris-HCl pH 7.4) and centrifuged at
200 × g for 2 minutes. The tubular suspensions were resuspended in buffer B and 500 μL was
transferred into individual tubes containing either DMSO (negative control) or different con-
centrations of CsA (final concentrations of 5, 10, or 20 μmol/L). Hypotonic low chloride
(buffer H), which stimulates NCC [41,42], was used as a positive control. Suspensions were
incubated with continuous mixing for 30 and 90 minutes at 37˚C. Tubules were centrifuged
for 10 minutes at 3,000 × g at 4˚C and pellets were resuspended in 300 μL Laemmli sample
buffer containing dithiothreitol (50 mg/mL). Finally, the samples were heated for 15 minutes
at 60˚C before immunoblotting.
Immunoblotting
uEV-samples were loaded on a gradient SDS-PAGE gel (4–15% v/v Criterion™ TGX™ Precast
Gel, Bio-Rad, The Netherlands). Loading of uEV-sample of each subject was normalized to
urinary creatinine concentration to account for uEV concentration differences between the
individual samples [26]. Subsequently, immunoblotting was performed on polyvinylidene
difluoride membranes (Immobilon-P, Millipore Corporation, Bedford, MA, USA), which
were blocked and probed with antigen-specific primary antibodies. Blots were incubated
with species-specific fluorescent secondary antibodies and visualized using enhanced chemilu-
minescence (Thermo Fischer Scientific, Waltham, MA, USA) and gel imaging system
(ChemiDoc XRS, Bio-Rad Laboratories, Hercules, CA, USA). Finally, both the dimeric and
monomeric forms of the NCC bands on the blots were quantified together with Image Studio
Lite software (LI-COR Biosciences, NE, USA) or ImageQuant TL (GE Healthcare Life Sci-
ences, PA, USA). To analyze whether normalization by urinary creatinine resulted in a similar
number of uEVs loaded on a gel, the abundance of the uEV-marker CD9 was measured
[26,30,43].
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Antibodies
The following antibodies were used: anti-total NCC (Millipore, Billerica, MA, USA, #AB3553;
1:2,000); anti-human phosphorylated NCC at Thr60 or (anti-mouse phosphorylated NCC at
Thr58; 1:2,000) as previously described [44] and anti-uEV marker CD9 of human origin (C4,
Santa Cruz Biotechnology, Inc., CA, USA; 1:500). Secondary antibodies used were peroxidase-
conjugated goat anti-rabbit (Sigma-Aldrich, St. Louis, MO, USA; 1:10,000), and anti-mouse
(Sigma-Aldrich, St. Louis, MO, USA; 1:10,000).
Statistical analysis
Values are expressed as mean ± SEM. In Group 1 the immunoblot data were analyzed by com-
paring integrated optical densities of bands by one-way ANOVA with Dunnett multiple com-
parisons post hoc test. In Group 2 the immunoblot data were analyzed using a non-parametric
Student’s t-test (comparing responders to non-responders). Two-way ANOVA was used to
assess changes in uEV protein abundance before and after the chlorthalidone treatment. In the
mouse study the immunoblot data were analyzed by comparing integrated optical densities of
bands after 30 and 90 minutes exposure to CsA separately compared to its negative control
(basic buffer without CsA) by one-way ANOVA with Dunnett multiple comparisons post hoc
test. In this study, fold-change of 1 means no change. P<0.05 was considered statistically sig-
nificant. All data were analyzed using Prism 5 software (GraphPad Software Inc, La Jolla, CA,
USA).
Results
CNIs increase NCC in uEVs of kidney transplant recipients
Table 1 shows the clinical and laboratory characteristics of 9 CsA, 23 Tac and 13 CNI-free
immunosuppressive regimens treated kidney transplant recipients (Group 1). The effect of
CNI on NCC abundance in uEVs was assessed using immunoblot analysis. Two immunoreac-
tive bands of ~260 and ~130 kDa representing the dimeric and monomeric forms of the NCC
protein were detected in uEVs (Fig 1). Both forms were included in the analysis to determine
the effect of CNI treatment on NCC abundance in uEVs. The abundances of tNCC and pNCC
in uEVs of both CsA and Tac-treated kidney transplant recipients were significantly higher
compared to uEVs isolated from kidney transplant recipients treated with CNI-free immuno-
suppressive regimens or healthy volunteers (Fig 2A and 2C). No significant difference in
tNCC and pNCC abundance was detected between CsA and Tac-treated kidney transplant
recipients. The ratio of pNCC to tNCC did not differ between kidney transplant recipients
treated with CsA, Tac, CNI-free immunosuppressive regimens, and healthy volunteers (Fig
2E). Females may express more NCC [45], but in our study a gender difference in the abun-
dance of NCC in the uEVs was not demonstrated (S1 Fig). No significant differences in CD9
abundance were observed between the four experimental groups, suggesting comparable uEV
numbers (Fig 2B and 2D). Additional normalization by CD9 abundance showed that both
tNCC (S2A Fig) and pNCC (S2B Fig) abundance in both CsA- and Tac-treated kidney trans-
plant recipients was significantly higher in comparison to kidney transplant recipients treated
with CNI-free immunosuppressive regimens, but not healthy volunteers.
NCC abundance in uEVs predicts the anti-hypertensive response to
thiazides
Subsequently, we investigated whether the blood pressure response to thiazide diuretics in
hypertensive kidney transplant recipients treated with Tac correlates with NCC abundance in
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uEVs. To this end, we compared tNCC and pNCC abundances in uEVs of patients with a
blood pressure response to a thiazide in comparison to those who did not respond. Table 2
shows the clinical and laboratory characteristics of these patients (Group 2). Pre-treatment
abundances of both tNCC and pNCC in uEVs were significantly higher in chlorthalidone
responders compared to non-responders (Fig 3). Furthermore, both pNCC and tNCC abun-
dance in uEVs correlated with the blood pressure response (R2 = 0.27 and 0.30 using log-
transformed densitometry data because of non-normal distribution, P<0.05 for both, Fig 3).
Subsequently, the change in NCC abundance before and after treatment with chlorthalidone
in uEVs of both responders and non-responders was compared (Fig 4 and S5 and S6 Figs,
show original immunoblots). The increase of tNCC in uEVs was larger in non-responders
than in responders (P<0.05). While pNCC in uEVs also increased in most responders, there
was a decrease in pNCC in the majority of non-responders (P<0.05). As a result, the pNCC to
tNCC ratio remained constant in the responders, but markedly decreased in non-responders
(P<0.05). This suggests that phospho-occupancy at the measured site was lower in non-
responders. No gender differences were found (S7 Fig). Again, no significant differences were
found in the abundances of CD9 between groups, suggesting comparable uEV-numbers (Fig 3
and S8 Fig). Additional normalization by CD9 abundance led to similar results (S9 Fig).
Increased pNCC in mouse cortical tubule suspensions exposed to CsA
To study the acute effect of CsA on NCC abundance in kidney, mouse cortical tubules were
isolated and exposed to CsA. All mouse cortical tubule suspensions were incubated in basic
buffer for 30 or 90 minutes in the absence or presence of CsA (at final concentrations of 5, 10,
and 20 μmol/L). No significant changes were observed in tNCC, while the pNCC abundance
Table 1. Clinical and laboratory characteristics of the patients in study Group 1.
Characteristic
(mean ± SEM)
CNI-free group
(n = 13)
CsA group
(n = 9)
Tac group
(n = 23)
P-value
Age 53 ± 3 51 ± 2 52 ± 3 0.90a, 0.96b
Male (n (%)) 7 (54) 5 (56) 12 (52)
Body mass index, Kg/m2 25 ± 1 27 ± 2 27 ± 1 0.53a, 0.38b
Cause of ESRD (n)
Polycystic kidney disease 3 1 5
Diabetes 0 2 2
Glomerular disease 2 0 0
Hypertension/Vascular 0 0 2
Other 8 6 14
Plasma sodium, mmol/L 140 ± 1 138 ± 1 139 ± 1 0.44a, 0.72b
Plasma potassium, mmol/L 4.0 ± 0.1 4.1 ± 0.1 4.1 ± 0.1 0.80a, 0.72b
Plasma chloride, mmol/L 106 ± 1 105 ± 1 108 ± 1 0.80a, 0.29b
Plasma creatinine, mg/dL 1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 0.80a, 0.72b
eGFR, mL/min/1.73 m2 46 ± 2 42 ± 3 45 ± 4 0.76a, 0.97b
Systolic blood pressure, mmHg 135 ± 3 137 ± 4 142 ± 3 0.91a, 0.22b
Diastolic blood pressure, mmHg 80 ± 2 84 ± 4 82 ± 2 0.52a, 0.77b
CsA pre-dose level, μg/L 127 ± 14
Tac pre   dose level;μg=L 6:7 ± 0:4
SEM = standard error of the mean; ESRD = end stage renal disease; data are presented as mean ± SEM.
a
= P-value for difference between CsA and CNI-free;
b
= P-value for difference between Tac and CNI-free, 95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0176220.t001
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and the ratio of pNCC to tNCC were significantly increased after 30 minutes of exposure to 10
or 20 μmol/L of CsA, and after 90 minutes of exposure to 5, 10, or 20 μmol/L of CsA (Fig 5).
Hypotonic low chloride, which decreases the intracellular chloride concentration thereby acti-
vating the WNK-SPAK and OSR1 pathways [41,42], was used as a positive control. pNCC and
the ratio of pNCC to tNCC were significantly increased in hypotonic low chloride buffer,
whereas tNCC remained unchanged (Fig 5).
Discussion
Our study demonstrates that chronic treatment with CNIs increases both tNCC and pNCC
abundance in uEVs of kidney transplant recipients, suggesting increased sodium reabsorption
in the distal part of the nephron. Additionally, we show that the increase in pNCC abundance
in uEVs of kidney transplant recipients correlates with the blood pressure response to NCC-
inhibiting thiazide diuretics. Lastly, we corroborate that CNIs activate NCC in the kidney by
showing that short-term exposure to cyclosporine increases pNCC but not tNCC abundance
in mouse cortical tubules suspensions. Collectively, these observations indicate that the CNI-
induced increase in NCC abundance and activity are involved in the pathogenesis of hyperten-
sion in kidney transplant recipients, and suggest that pNCC abundance in uEVs could be used
as a biomarker to predict the blood pressure response to thiazide diuretics.
Since the introduction of CNIs in the 1980s, there has been a steep increase in the preva-
lence of hypertension after kidney transplantation [46,47]. In a study using a kidney specific
12 kDa FK506-binding protein, FKBP12, knockout mice, Tac caused hypertension by inhibit-
ing calcineurin directly in DCT cells expressing NCC [22]. Moreover, NCC knockout mice
Fig 1. Representative immunoblots of tNCC and pNCC abundance in uEVs of kidney transplant recipients treated with CsA,
Tac or CNI-free immunosuppressive regimens and healthy volunteers. Panels A and B show the immunoreactive bands in
uEVs of patients treated with CsA (n = 4), Tac (n = 5), CNI-free immunosuppressive regimens (n = 3), and healthy volunteers (n = 5).
tNCC (A) and pNCC (B) immunoreactive bands in uEVs of both CsA- and Tac-treated kidney transplant recipients were more
abundant compared to kidney transplant recipients treated with CNI-free immunosuppressive regimens and healthy volunteers.
https://doi.org/10.1371/journal.pone.0176220.g001
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Fig 2. Densitometry of tNCC and pNCC immunoreactive bands in uEVs of all kidney transplant recipients treated with CsA
(n = 9), Tac (n = 23) or CNI-free immunosuppressive regimens (n = 13) and healthy volunteers (n = 6). Both tNCC (A) and
pNCC (C) abundance in both CsA- and Tac-treated kidney transplant recipients was significantly higher in comparison to kidney
transplant recipients treated with CNI-free immunosuppressive regimens and healthy volunteers. Densitometry analysis of CD9
expression of the immunoblots for tNCC (B) and pNCC (D) showed no significant differences between the four groups. The ratio of
pNCC to tNCC abundance in uEVs of CsA- and Tac-treated group was not significantly higher in comparison to kidney transplant
recipients treated with CNI-free immunosuppressive regimens and healthy volunteers (E). The original immunoblots are shown in Fig
1 and S3 and S4 Figs. Values are mean ± SEM normalized to kidney transplant recipients treated with CNI-free immunosuppressive
regimens (one-way ANOVA, *P<0.05, n = 51).
https://doi.org/10.1371/journal.pone.0176220.g002
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were protected from tacrolimus-induced hypertension [21], confirming the role of NCC in
CNI-induced hypertension. Although both CsA and Tac inhibit calcineurin, they differ in
structure and cytoplasmic binding protein, which might explain why hypertension is less com-
mon and less severe in patients using Tac than in those using CsA [2,6–8,10,48]. However, it is
still not known whether the higher incidence of hypertension in CsA- compared to Tac-treated
kidney transplant recipients is due to a stronger tNCC and pNCC upregulation. Our study
demonstrates that CsA does not increase tNCC and pNCC abundances in uEVs of kidney
transplant recipients more than Tac (Fig 2). This suggests that factors other than NCC might
contribute to the discrepancy in the increased blood pressure between patient groups using
CsA and Tac. It is known that CNIs affect tissues other than the kidney, which are also
involved in the development of hypertension [22]. CsA and Tac might differ in their ability to
cause vasoconstriction [49,50], activate the renin-angiotensin-aldosterone system (RAAS)
[21,50], or the sympathetic nervous system [51], all of which can contribute to the develop-
ment of hypertension.
Several guidelines recommend thiazide-type diuretics as first-line treatment for the man-
agement of hypertension in adults [52,53]. Thiazide-type diuretics act by blocking NCC, thus
increasing sodium excretion by the kidney [54]. Given the role of NCC in CNI-induced hyper-
tension, thiazide diuretics might be especially effective drugs for hypertensive transplant
recipients using CNIs and NCC abundance in their uEVs might predict the blood pressure
response to thiazide diuretics. Indeed, uEV analysis in patients selected from our crossover
study demonstrates that pre-treatment abundances of tNCC and pNCC in uEVs predict the
blood pressure response to thiazide diuretics (Fig 3). This implies that the abundance of pNCC
in uEVs of hypertensive kidney transplant recipients using CNIs could be used to predict thia-
zide sensitivity. Although it may be more pragmatic to simply test the response to a trial of
Table 2. Clinical and laboratory characteristics of the patients in study Group 2.
Characteristic
(mean ± SEM)
Responders
(n = 10)
Non-responders
(n = 8)
P-value
Age 61 ± 2 57 ± 3 0.15
Males (n (%)) 6 (60) 6 (75) 0.27
Body mass index, Kg/m2 27 ± 2 30 ± 2 0.14
Cause of ESRD (n)
Polycystic kidney disease 1 0
Diabetes 2 3
Glomerular disease 0 3
Hypertension/vascular 6 1
Other 1 1
Plasma sodium, mmol/L 140 ± 1 140 ± 1 0.40
Plasma potassium, mmol/L 4.5 ± 0.1 5.1 ± 0.2* <0.01
Plasma chloride, mmol/L 103 ± 1 105 ± 1 0.07
Plasma creatinine, mg/dL 1.2 ± 0.1 1.7 ± 0.2* 0.01
eGFR, mL/min/1.73 m2 55 ± 5 43 ± 6 0.06
Urine K/creatinine, mmol/mmol 5.2 ± 2.1 4.6 ± 1.9 0.28
Systolic blood pressure, mmHg 158 ± 4 151 ± 5 0.15
Diastolic blood pressure, mmHg 86 ± 2 80 ± 3 0.07
Tac pre-dose level, μg/L 5.5 ± 0.4 5.8 ± 0.5 0.30
SEM = standard error of the mean; ESRD = end stage renal disease; data are presented as mean ± SEM. P-value for difference between responders and
non-responders, 95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0176220.t002
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Fig 3. Pre-treatment tNCC and pNCC abundances in uEVs isolated from hypertensive kidney transplant recipients who did
or did not respond to chlorthalidone. Shown are immunoblots of tNCC (panel A) and pNCC (panel B) together with CD9 in uEVs
of hypertensive kidney transplant recipients using Tac. ‘Responders’ (n = 10) refer to patients who subsequently had a significant
anti-hypertensive response (10 mmHg reduction in systolic blood pressure) to 8-week treatment with chlorthalidone. Non-
responders (n = 8) did not have an anti-hypertensive response to chlorthalidone (no change or increase in systolic blood pressure).
uEVs were isolated before the treatment with chlorthalidone. Both tNCC and pNCC abundance were significantly higher in
responders compared to non-responders (non-parametric t-test, *P<0.05, n = 18). Both pNCC and tNCC abundance in uEVs
correlated with the blood pressure response (panel C, R2 = 0.27 and panel D, R2 = 0.30 using log-transformed densitometry data
because of non-normal distribution, P<0.05 for both). Abbreviations: SBP, ambulatory systolic blood pressure.
https://doi.org/10.1371/journal.pone.0176220.g003
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Fig 4. pNCC and tNCC abundances in uEVs before and after treatment with chlorthalidone. Panel A shows
pNCC and tNCC abundances in uEVs before (B) and after (A) the 8-week treatment period with chlorthalidone in both
responders (n = 10) and non-responders (n = 8). The fold-changes in the before-after abundances of pNCC and tNCC
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thiazide diuretics, urinary biomarkers may help individualize anti-hypertensive treatment,
especially with the development of high-throughput assays [55]. However, acute regulators of
NCC activity such as the RAAS and potassium status should also be taken into account when
interpreting the obtained results (see below). A relevant question is what explains the higher
pNCC and tNCC in uEVs of responders prior to treatment, and the decrease in ratio of pNCC
to tNCC in non-responders after thiazide treatment. One could argue that CNI-induced NCC
activation was greater in responders. An alternative possibility is that the potassium balance
determined thiazide sensitivity. A high potassium diet and hyperkalemia have recently been
shown to inhibit NCC [56,57]. Indeed, serum potassium concentrations were higher in non-
responders compared to responders. Here, we show that NCC abundance was increased in
the majority of “responders” after thiazide treatment (Fig 4), which is consistent with data
obtained in animal models [58,59]. Na et al. showed with immunoblot analysis and immunos-
taining that chronic hydrochlorothiazide treatment in rats increased the abundance of NCC
[58]. Moreover, chronic hydrochlorothiazide infusion in mice increased the binding density of
[3H] metolazone, an indirect measure of NCC activity, which confirms the increase of NCC
after hydrochlorothiazide [60]. Similarly, chronic administration of the diuretics furosemide
and amiloride (which blocks the Na-K-Cl cotransporter and ENaC, respectively), increased
the abundance of these proteins in rodent kidney [58,61]. These effects might be the result of
compensatory mechanisms, potentially mediated by the RAAS or/and potassium balance,
which counteract reduced NCC function by the thiazide treatment [62]. Of interest, non-
responders had a completely different pattern during thiazide treatment with a decrease in
pNCC and ratio of pNCC to tNCC (Fig 4). The explanation for this difference is unclear, but
one might speculate that a blood pressure response to thiazides is accompanied by RAAS acti-
vation resulting in different NCC excretion patterns in uEVs. Alternatively, differences in
potassium balance may explain these results, because a recent study showed that pNCC stimu-
lation by angiotensin II occurs as a compensatory response to renal potassium loss [63].
To further confirm the effect of CNIs on NCC in the kidney, we performed an ex vivo study
using mice cortical tubules. This experiment demonstrated that short-term exposure to CsA
increases pNCC abundance, while tNCC remained stable (Fig 5). This phenomenon was previ-
ously reported by Hoorn et al. [21] in mice and human embryonic kidney 293 cells treated
with Tac, and by Melnikov et al. [23] in mDCT cells treated with CsA. Recently, it was demon-
strated in mice that treatment with Tac prevents the acute high potassium induced NCC
dephosphorylation, while tNCC remained unaffected [24]. In contrast to previous studies,
this acute regulatory system mediated by calcineurin is shown to be independent of the
WNK-SPAK signaling cascade [24]. Our study demonstrated that chronic administration of
CNIs increases the abundance of both tNCC and pNCC in uEVs of kidney transplant recipi-
ents. This suggests that the difference in tNCC increase between mice cortical tubules and
uEVs might be dependent on the time of stimulation or another signaling molecule involved
in the in vivo situation.
A number of limitations of our study should be mentioned. First, several other factors,
in addition to CNIs, may regulate NCC, which may also explain differences in expression
of NCC and in thiazide sensitivity. Second, an unresolved question in the uEV-field remains
whether the abundance of protein per uEV varies, or that the number of uEVs is regulated.
in uEVs (as measured by densitometry) of both responders and non-responders are shown in panel B (Fold-change of
1 means no change, *P<0.05). The scatter plots represent the fold change in tNCC, pNCC or their ratio after treatment
with chlorthalidone (densitometry values before treatment with chlorthalidone were set to 1). S5 and S6 Figs, show the
original immunoblots from which the individual panels in Fig 4A were derived.
https://doi.org/10.1371/journal.pone.0176220.g004
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Fig 5. tNCC and pNCC abundance in mouse cortical tubule suspension exposed to CsA. Panel A shows representative
immunoblots of tNCC and pNCC abundance in mouse cortical tubule suspension exposed to CsA. Immunoblots of protein
homogenates of mouse cortical tubule suspensions were incubated in basic (B) buffer for 30 and 90 minutes, in the absence (-) or
presence of CsA at final concentrations of 5, 10, or 20 μmol/L (A). tNCC remained at baseline levels (B), while pNCC (C) and ratio of
pNCC to tNCC (D) were significantly increased in the mouse cortical tubule suspension after 30 minutes of exposure to 10 and
20 μmol/L of CsA and 90 minutes of exposure to 5, 10, and 20 μmol/L of CsA. Similarly, pNCC and the ratio of pNCC to tNCC were
significantly increased in hypotonic low chloride (H) buffer (C and D). The original immunoblots for 30 and 90 minutes, in the
absence (-) or presence of CsA at final concentrations of 5, 10, or 20 μmol/L are shown in Fig 5 and S10 Fig. Values are
mean ± SEM normalized to basic (B) condition (one-way ANOVA, *P<0.05, 30 minutes exposure n = 3, 90 minutes exposure n = 4).
https://doi.org/10.1371/journal.pone.0176220.g005
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Although we included the uEV-marker CD9, techniques that allow uEV counting will be
necessary to address this point more conclusively.
Conclusions
Our findings demonstrate that CNI treatment increases both tNCC and pNCC abundance
in uEVs isolated from kidney transplant recipients. We also show that the blood pressure
response to chlorthalidone in Tac-treated hypertensive kidney transplant recipients was
related to the pNCC abundance in uEVs. This implies that pNCC in uEVs of kidney transplant
recipients treated with a CNI might be used to predict blood pressure response to thiazide
diuretics. In addition, uEV analysis may have clinical utility as a non-invasive biomarker for a
variety of physiological and pathological conditions.
Supporting information
S1 Excel. Excel file show the optical densitometry of Fig 1 and S3 and S4 Figs. Both the
dimeric and monomeric forms of the tNCC and pNCC bands on the blots were quantified
together with Image Studio Lite software (LI-COR Biosciences, NE, USA).
(XLSX)
S2 Excel. Excel file show the optical densitometry of Fig 5 and S10 Fig. tNCC and pNCC
bands on the blots were quantified with Image Studio Lite software (LI-COR Biosciences, NE,
USA).
(XLSX)
S3 Excel. This excel file shows the optical densitometry data of Figs 3 and 4 and S5, S6 and
S8 Figs. Both the dimeric and monomeric forms of the tNCC and pNCC bands on the blots
were quantified together.
(XLSX)
S4 Excel. This excel file shows the optical densitometry data of S7 Fig. It contains the data
of tNCC and pNCC in responders compared to non-responders for both males and females
separately.
(XLSX)
S5 Excel. This excel file shows the optical densitometry data of S9 Fig. It contains the data
of tNCC and pNCC normalized to CD9.
(XLSX)
S1 Fig. Males versus females densitometry of tNCC and pNCC immunoreactive bands in
uEVs of all kidney transplant recipients treated with CsA (male n = 5, female n = 4), Tac
(male n = 7, female n = 6) or CNI-free immunosuppressive regimens (male n = 12, female
n = 11) and healthy volunteers (male n = 6, female n = 0). Both in males and females tNCC
(A and B) and pNCC (C and D) abundance in both CsA- and Tac-treated kidney transplant
recipients was significantly higher in comparison to kidney transplant recipients treated with
CNI-free immunosuppressive regimens. The ratio of pNCC to tNCC abundance in uEVs of
CsA- and Tac-treated group was not significantly more abundant in comparison to kidney
transplant recipients treated with CNI-free immunosuppressive regimens (E-F). The original
immunoblots, are shown in Fig 1 and S3 and S4 Figs. Densitometry data are shown in S1
Excel. Values are mean ± SEM normalized to kidney transplant recipients treated with CNI-
free immunosuppressive regimens (one-way ANOVA, P<0.05, n = 51).
(TIF)
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S2 Fig. Densitometry of tNCC and pNCC immunoreactive bands in uEVs of all kidney
transplant recipients treated with CsA (n = 9), Tac (n = 13) or CNI-free immunosuppres-
sive regimens (n = 21) and healthy volunteers (n = 6). The volume of uEV suspension per
sample was adjusted according to the urinary creatinine concentration and loaded on gels for
immunoblot analysis. Densitometry analysis of the immunoblots for the abundance of tNCC
(A) and pNCC (B). Both the dimer and monomer bands were analyzed together. The original
immunoblots are shown in Fig 1 and S3 and S4 Figs. The abundance of both tNCC and pNCC
was normalized to CD9 abundance after normalization by urinary creatinine. Densitometry
data are shown in S1 Excel. Values are mean ± SEM normalized to kidney transplant recipients
treated with CNI-free immunosuppressive regimens (one-way ANOVA, P<0.05, n = 51).
(TIF)
S3 Fig. Immunoblots of tNCC abundance in uEVs of kidney transplant recipients treated
with CsA, Tac or CNI-free immunosuppressive regimens and healthy volunteers (A-D).
uEV samples with a mark of # were loaded twice as a control on the gel, although these samples
were excluded from densitometry analysis. Densitometry data are shown in S1 Excel.
(TIF)
S4 Fig. Immunoblots of pNCC abundance in uEVs of kidney transplant recipients treated
with CsA, Tac or CNI-free immunosuppressive regimens and healthy volunteers (A-C).
uEV samples with a mark of # were loaded twice as a control on the gel, although these samples
were excluded from densitometry analysis. Densitometry data are shown in S1 Excel.
(TIF)
S5 Fig. This figure shows how Fig 4A was created. We used pNCC in uEVs before and after
chlorthalidone treatment of responders (A) and non-responders (B).
(TIF)
S6 Fig. This figure shows how Fig 4A was created. We used tNCC in uEVs before and after
chlorthalidone treatment of responders (A) and non-responders (B).
(TIF)
S7 Fig. This figure depicts the densitometry results of tNCC and pNCC comparable to Fig
3A and 3B, but separated into male and female. Panel A and C show tNCC and pNCC in
males for responders (n = 6) compared to non-responders (n = 6). Panel B and D show tNCC
and pNCC in females for responders (n = 4) compared to non-responders (n = 2). The non-
parametric t-test was used for the analysis of all the graphs in this figure, P<0.05.
(TIF)
S8 Fig. This figure shows the immunoblots of CD9 abundance of Fig 4A and S5 and S6
Figs. The abundance of CD9 was comparable before and after chlorthalidone treatment of
responders (A) and non-responders (B).
(TIF)
S9 Fig. This figure depicts the densitometry results of tNCC and pNCC normalized to
CD9. tNCC and pNCC normalized to CD9 abundance of both responders and non-respond-
ers that are depicted in panel A and B (n = 18 for both). Panel C and D show the data for
tNCC and pNCC normalized to CD9 in responders before and after treatment with chlorthali-
done (n = 20 for both). Panel E and F show the data for tNCC and pNCC normalized to CD9
in non-responders before and after treatment with chlorthalidone (n = 16 for both). The non-
parametric t-test was used for the analysis of all the graphs in this figure, P<0.05.
(TIF)
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S10 Fig. This figure shows the immunoblots tNCC and pNCC abundance in mouse cortical
tubule suspension exposed to CsA. Immunoblots of protein homogenates of mouse cortical
tubule suspensions were incubated in basic (B) buffer for 30 (A-C) and 90 minutes (C-F), in
the absence (-) or presence of CsA at final concentrations of 5, 10, or 20 μmol/L. Densitometry
data are shown in S2 Excel.
(TIF)
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